|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 3/08/17 American Renal Assocs Holdin… Inc 10-K 12/31/16 97:12M |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 2.15M
2: EX-21.1 Subsidiaries List HTML 106K
3: EX-23.1 Consent of Experts or Counsel HTML 26K
4: EX-31.1 Certification -- §302 - SOA'02 HTML 34K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 33K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 30K
7: EX-32.2 Certification -- §906 - SOA'02 HTML 29K
14: R1 Document and Entity Information HTML 53K
15: R2 Consolidated Balance Sheets HTML 119K
16: R3 Consolidated Balance Sheets (Parenthetical) HTML 44K
17: R4 Consolidated Statements of Operations HTML 94K
18: R5 Consolidated Statements of Comprehensive Income HTML 41K
19: R6 Consolidated Statements of Changes in Equity HTML 144K
20: R7 Consolidated Statements of Changes in Equity HTML 29K
(Parenthetical)
21: R8 Consolidated Statements of Cash Flows HTML 156K
22: R9 Presentation HTML 30K
23: R10 Summary of Significant Accounting Policies HTML 85K
24: R11 Initial Public Offering HTML 43K
25: R12 Acquisitions HTML 53K
26: R13 Fair Value of Financial Instruments HTML 114K
27: R14 Property and Equipment HTML 44K
28: R15 Intangible Assets and Goodwill HTML 73K
29: R16 Accrued Expenses and Other Current Liabilities HTML 51K
30: R17 Variable Interest Entities HTML 35K
31: R18 Noncontrolling Interests Subject to Put Provisions HTML 32K
32: R19 Changes in Ownership Interest in Consolidated HTML 50K
Subsidiaries
33: R20 Debt HTML 81K
34: R21 Leases HTML 65K
35: R22 Income Taxes HTML 118K
36: R23 Earnings (Loss) Per Share HTML 91K
37: R24 Equity HTML 38K
38: R25 Stock-Based Compensation HTML 142K
39: R26 Related Party Transactions HTML 40K
40: R27 Commitments and Contingencies HTML 34K
41: R28 Certain Legal Matters HTML 38K
42: R29 Employee Benefit Plan HTML 29K
43: R30 Concentrations HTML 31K
44: R31 Selected Quarterly Financial Data (Unaudited) HTML 106K
45: R32 Summary of Significant Accounting Policies HTML 114K
(Policies)
46: R33 Summary of Significant Accounting Policies HTML 30K
(Tables)
47: R34 Acquisitions (Tables) HTML 42K
48: R35 Fair Value of Financial Instruments (Tables) HTML 106K
49: R36 Property and Equipment (Tables) HTML 41K
50: R37 Intangible Assets and Goodwill (Tables) HTML 72K
51: R38 Accrued Expenses and Other Current Liabilities HTML 52K
(Tables)
52: R39 Changes in Ownership Interest in Consolidated HTML 51K
Subsidiaries (Tables)
53: R40 Debt (Tables) HTML 74K
54: R41 Leases (Tables) HTML 60K
55: R42 Income Taxes (Tables) HTML 118K
56: R43 Earnings (Loss) Per Share (Tables) HTML 88K
57: R44 Stock-Based Compensation (Tables) HTML 126K
58: R45 Selected Quarterly Financial Data (Unaudited) ( HTML 105K
Tables)
59: R46 Presentation (Details) HTML 37K
60: R47 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 36K
Accounts Receivable (Details)
61: R48 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 34K
Property and Equipment (Details)
62: R49 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 30K
Amortizable Intangible Assets (Details)
63: R50 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 27K
Identified Non Amortizable Intangible Assets and
Goodwill (Details)
64: R51 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 39K
Impairment of Long Lived Assets (Details)
65: R52 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 39K
Recent Accounting Pronouncements (Details)
66: R53 Initial Public Offering (Details) HTML 126K
67: R54 Acquisitions (Details) HTML 49K
68: R55 Fair Value of Financial Instruments (Details) HTML 79K
69: R56 Property and Equipment (Details) HTML 48K
70: R57 Intangible Assets and Goodwill (Details) HTML 49K
71: R58 Intangible Assets and Goodwill - Estimated annual HTML 42K
amortization expense (Details)
72: R59 INTANGIBLE ASSETS AND GOODWILL - Changes in the HTML 33K
value of goodwilll (Details)
73: R60 Accrued Expenses and Other Current Liabilities HTML 46K
(Details)
74: R61 Variable Interest Entities (Details) HTML 29K
75: R62 Noncontrolling Interests Subject to Put Provisions HTML 38K
(Details)
76: R63 Changes in Ownership Interest in Consolidated HTML 44K
Subsidiaries (Details)
77: R64 Debt (Details) HTML 67K
78: R65 Debt - Credit And Interest Rate Swap Agreements HTML 106K
(Detail)
79: R66 Leases (Details) HTML 102K
80: R67 Income Taxes (Details) HTML 47K
81: R68 Income Taxes - Significant components of deferred HTML 66K
tax assets and liabilities (Details)
82: R69 INCOME TAXES - Reconciliation of the federal HTML 49K
statutory rate (Details)
83: R70 Earnings (Loss) Per Share (Details) HTML 68K
84: R71 Equity (Details) HTML 48K
85: R72 STOCK-BASED COMPENSATION - Share Based HTML 51K
Compensation Plans & Shares reserved (Details)
86: R73 STOCK BASED COMPENSATION - Equity Grants, HTML 33K
Assumptions and Activity (Details)
87: R74 STOCK-BASED COMPENSATION - Weighted - average HTML 101K
assumptions and stock option activity (Details)
88: R75 STOCK BASED COMPENSATION - Stock options and HTML 38K
compensation costs (Details)
89: R76 Related Party Transactions (Details) HTML 80K
90: R77 Commitments and Contingencies (Details) HTML 29K
91: R78 Certain Legal Matters (Details) HTML 32K
92: R79 Employee Benefit Plan (Details) HTML 27K
93: R80 Concentrations (Details) HTML 26K
94: R81 Selected Quarterly Financial Data (Unaudited) HTML 49K
(Details)
96: XML IDEA XML File -- Filing Summary XML 171K
95: EXCEL IDEA Workbook of Financial Reports XLSX 105K
8: EX-101.INS XBRL Instance -- ara-20161231 XML 2.23M
10: EX-101.CAL XBRL Calculations -- ara-20161231_cal XML 277K
11: EX-101.DEF XBRL Definitions -- ara-20161231_def XML 609K
12: EX-101.LAB XBRL Labels -- ara-20161231_lab XML 1.70M
13: EX-101.PRE XBRL Presentations -- ara-20161231_pre XML 1.15M
9: EX-101.SCH XBRL Schema -- ara-20161231 XSD 198K
97: ZIP XBRL Zipped Folder -- 0001498068-17-000012-xbrl Zip 202K
| ara_Ex31-2 |
Exhibit 31.2
SECTION 302 CERTIFICATION
I, Jonathan L. Wilcox, certify that:
|
1. |
I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2016 of American Renal Associates Holdings, Inc. (the “registrant”); |
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
4. |
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)) and 15d-15(e)) for the registrant and have: |
|
(a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
(b) |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
(c) |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
|
5. |
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|
(a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
|
(b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
|
Chief Financial Officer |
Date: March 8, 2017
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/8/17 | None on these Dates | ||
| For Period end: | 12/31/16 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/07/17 SEC UPLOAD¶ 10/07/17 1:35K American Renal Assocs Holdin… Inc 7/20/17 SEC UPLOAD¶ 10/07/17 1:137K American Renal Assocs Holdin… Inc 6/26/17 SEC UPLOAD¶ 10/07/17 1:139K American Renal Assocs Holdin… Inc 5/25/17 SEC UPLOAD¶ 10/07/17 1:139K American Renal Assocs Holdin… Inc |